Department of Obstetrics, Gynecology, and Reproductive Sciences, Icahn School of Medicine at Mount Sinai, Reproductive Medicine Associates of New York, and the Department of Obstetrics, Gynecology, and Reproductive Sciences, Mount Sinai West, New York, New York.
Obstet Gynecol. 2022 Apr 1;139(4):490-497. doi: 10.1097/AOG.0000000000004713. Epub 2022 Jan 25.
To assess whether coronavirus disease 2019 (COVID-19) mRNA vaccination is associated with controlled ovarian hyperstimulation or early pregnancy outcomes.
This retrospective cohort study included patients who underwent controlled ovarian hyperstimulation or single euploid frozen-thawed embryo transfer at a single academic center. Patients fully vaccinated with a COVID-19 mRNA vaccine were compared with unvaccinated patients who cycled during the same time period. The primary outcome was the fertilization rate for controlled ovarian hyperstimulation and the clinical pregnancy rate for frozen-thawed embryo transfer. Secondary outcomes for controlled ovarian hyperstimulation included eggs retrieved, mature oocytes retrieved, mature oocytes ratio, blastulation rate, and euploid rate. Secondary outcomes for frozen-thawed embryo transfer included pregnancy rate, ongoing pregnancy rate, biochemical pregnancy loss rate, and clinical pregnancy loss rate.
Among 222 vaccinated patients and 983 unvaccinated patients who underwent controlled ovarian hyperstimulation cycles between February and September 2021, there was no association on adjusted analysis between COVID-19 vaccination and fertilization rate (β=0.02±0.02, P=.20) or any of the secondary outcomes assessed: eggs retrieved (β=0.01±0.57, P=.99), mature oocytes retrieved (β=0.26±0.47, P=.58), mature oocytes ratio (β=0.02±0.01, P=.12), blastulation rate (β=0.02±0.02, P=.27), or euploid rate (β=0.05±0.03, P=.08). Among 214 vaccinated patients and 733 unvaccinated patients undergoing single euploid frozen-thawed embryo transfer, adjusted analysis demonstrated no significant association between vaccination and clinical pregnancy (adjusted odds ratio [aOR] 0.79, 95% CI 0.54-1.16) or any of the secondary outcomes: pregnancy (aOR 0.88, 95% CI 0.58-1.33), ongoing pregnancy (aOR 0.90, 95% CI 0.61-1.31), biochemical pregnancy loss (aOR 1.21, 95% CI 0.69-2.14), or clinical pregnancy loss (aOR 1.02, 95% CI 0.51-2.06).
Administration of COVID-19 mRNA vaccines was not associated with an adverse effect on stimulation or early pregnancy outcomes after IVF. Our findings contribute to the growing body of evidence regarding the safety of COVID-19 vaccination in women who are trying to conceive.
评估 2019 年冠状病毒病(COVID-19)mRNA 疫苗接种是否与控制性卵巢过度刺激或早期妊娠结局有关。
本回顾性队列研究纳入了在一家学术中心接受控制性卵巢过度刺激或单枚整倍体冷冻胚胎移植的患者。将完全接种 COVID-19 mRNA 疫苗的患者与同期接受治疗但未接种疫苗的患者进行比较。主要结局是控制性卵巢过度刺激的受精率和冷冻胚胎移植的临床妊娠率。控制性卵巢过度刺激的次要结局包括取卵数、可成熟卵母细胞数、可成熟卵母细胞比例、囊胚形成率和整倍体率。冷冻胚胎移植的次要结局包括妊娠率、持续妊娠率、生化妊娠丢失率和临床妊娠丢失率。
在 2021 年 2 月至 9 月期间接受控制性卵巢过度刺激周期的 222 名接种疫苗患者和 983 名未接种疫苗患者中,调整分析显示 COVID-19 疫苗接种与受精率(β=0.02±0.02,P=.20)或任何评估的次要结局之间无关联:取卵数(β=0.01±0.57,P=.99)、可成熟卵母细胞数(β=0.26±0.47,P=.58)、可成熟卵母细胞比例(β=0.02±0.01,P=.12)、囊胚形成率(β=0.02±0.02,P=.27)或整倍体率(β=0.05±0.03,P=.08)。在 214 名接种疫苗患者和 733 名未接种疫苗患者中,进行单枚整倍体冷冻胚胎移植的调整分析显示,疫苗接种与临床妊娠(调整后的优势比[aOR]0.79,95%置信区间[CI]0.54-1.16)或任何次要结局之间无显著关联:妊娠(aOR 0.88,95% CI 0.58-1.33)、持续妊娠(aOR 0.90,95% CI 0.61-1.31)、生化妊娠丢失(aOR 1.21,95% CI 0.69-2.14)或临床妊娠丢失(aOR 1.02,95% CI 0.51-2.06)。
接受 COVID-19 mRNA 疫苗接种不会对体外受精后的刺激或早期妊娠结局产生不良影响。我们的研究结果为越来越多的关于 COVID-19 疫苗接种在试图怀孕的女性中的安全性的证据做出了贡献。